Metastasis: When good drugs do bad things Export

@article{citeulike:4219523, abstract = {Therapies aimed at inhibiting angiogenesis by targeting the vascular endothelial growth factor A (VEGFA)\&\#19;VEGFR2 (VEGF receptor 2) pathway have been beneficial in treating several types of cancers. However, the benefits are often short lived, and various adaptive mechanisms eventually lead to}, author = {Seton-Rogers, Sarah}, citeulike-article-id = {4219523}, citeulike-linkout-0 = {http://dx.doi.org/10.1038/nrc2632}, citeulike-linkout-1 = {http://www.sciencemag.org/content/vol323/issue5922/twil.dtl}, citeulike-linkout-2 = {http://www.f1000medicine.com/guardpages/evaluation/1158596/}, citeulike-linkout-3 = {http://www.ncbi.nlm.nih.gov/sites/entrez/19249681}, citeulike-linkout-4 = {http://www.growth-factors.net/showabstract.php?metaid=178882}, citeulike-linkout-5 = {http://www.nature.com/nrc/focus/migration/index.html}, comment = {and related: http://www.nature.com/news/2009/012345/full/458686b.html Nature 8 April 2009 | Nature 458, 686-687 (2009) | doi:10.1038/458686b CUTTING OFF CANCER'S SUPPLY LINES <Targeting the blood vessels that feed tumours is not the silver bullet once hoped for, but refinements to the strategy may suggest further ways to treat the disease.> Erika Check Hayden Drugs that aim to choke off a tumour's blood supply, known as angiogenesis inhibitors, have been hailed as opening a new era in cancer therapy. But a flurry of animal studies suggests that such drugs may in certain situations actually accelerate the spread of cancer. }, doi = {10.1038/nrc2632}, issn = {1474-175X}, journal = {Nature Reviews Cancer}, keywords = {anti-integrin, anti-vegf-mech, drug-sideffects, hgf\_met, metastasis, warburg}, number = {4}, pages = {228--229}, posted-at = {2009-04-17 19:01:11}, priority = {2}, publisher = {Nature Publishing Group}, title = {Metastasis: When good drugs do bad things}, url = {http://dx.doi.org/10.1038/nrc2632}, volume = {9} }

TY - JOUR ID - citeulike:4219523 L3 - citeulike-article-id:4219523 N2 - Therapies aimed at inhibiting angiogenesis by targeting the vascular endothelial growth factor A (VEGFA)&#19;VEGFR2 (VEGF receptor 2) pathway have been beneficial in treating several types of cancers. However, the benefits are often short lived, and various adaptive mechanisms eventually lead to IS - 4 JF - Nature Reviews Cancer SN - 1474-175X EP - 229 TI - Metastasis: When good drugs do bad things PB - Nature Publishing Group VL - 9 SP - 228 KW - anti-integrin KW - anti-vegf-mech KW - drug-sideffects KW - hgf_met KW - metastasis KW - warburg N1 - and related: http://www.nature.com/news/2009/012345/full/458686b.html Nature 8 April 2009 | Nature 458, 686-687 (2009) | doi:10.1038/458686b CUTTING OFF CANCER'S SUPPLY LINES <Targeting the blood vessels that feed tumours is not the silver bullet once hoped for, but refinements to the strategy may suggest further ways to treat the disease.> Erika Check Hayden Drugs that aim to choke off a tumour's blood supply, known as angiogenesis inhibitors, have been hailed as opening a new era in cancer therapy. But a flurry of animal studies suggests that such drugs may in certain situations actually accelerate the spread of cancer. AU - Seton-Rogers, Sarah UR - http://dx.doi.org/10.1038/nrc2632 ER -